Does the media prefer TENX or IMCR?

In the previous week, Tenax Therapeutics had 8 more articles in the media than Immunocore. MarketBeat recorded 17 mentions for Tenax Therapeutics and 9 mentions for Immunocore. Tenax Therapeutics' average media sentiment score of 0.75 beat Immunocore's score of 0.66 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or TENX more profitable?

Generate Biomedicines' return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Tenax Therapeutics N/A -63.18% -58.93%

Does the media refer more to GENB or TENX?

In the previous week, Tenax Therapeutics had 15 more articles in the media than Generate Biomedicines. MarketBeat recorded 17 mentions for Tenax Therapeutics and 2 mentions for Generate Biomedicines. Tenax Therapeutics' average media sentiment score of 0.75 beat Generate Biomedicines' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TENX or ZYME?

In the previous week, Tenax Therapeutics had 11 more articles in the media than Zymeworks. MarketBeat recorded 17 mentions for Tenax Therapeutics and 6 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.13 beat Tenax Therapeutics' score of 0.75 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or TENX?

In the previous week, Tenax Therapeutics had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 17 mentions for Tenax Therapeutics and 11 mentions for Sarepta Therapeutics. Tenax Therapeutics' average media sentiment score of 0.75 beat Sarepta Therapeutics' score of 0.69 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TENX or BHC?

In the previous week, Bausch Health Cos had 13 more articles in the media than Tenax Therapeutics. MarketBeat recorded 30 mentions for Bausch Health Cos and 17 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.75 beat Bausch Health Cos' score of 0.33 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 6 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Tenax Therapeutics (TENX) Competitors

$14.33 +0.63 (+4.60%)

Closing price 04:00 PM Eastern

Extended Trading

$14.44 +0.12 (+0.80%)

As of 04:45 PM Eastern

Compare

TENX vs. IMCR, GENB, ZYME, SRPT, and BHC

Should you buy Tenax Therapeutics stock or one of its competitors? MarketBeat compares Tenax Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenax Therapeutics include Immunocore (IMCR), Generate Biomedicines (GENB), Zymeworks (ZYME), Sarepta Therapeutics (SRPT), and Bausch Health Cos (BHC).

How does Tenax Therapeutics compare to Immunocore?

Tenax Therapeutics (NASDAQ:TENX) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Tenax Therapeutics had 8 more articles in the media than Immunocore. MarketBeat recorded 17 mentions for Tenax Therapeutics and 9 mentions for Immunocore. Tenax Therapeutics' average media sentiment score of 0.75 beat Immunocore's score of 0.66 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunocore has higher revenue and earnings than Tenax Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Immunocore	$412.81M	4.00	-$35.51M	-$0.55	N/A

Tenax Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Tenax Therapeutics presently has a consensus target price of $37.67, suggesting a potential upside of 162.85%. Immunocore has a consensus target price of $56.29, suggesting a potential upside of 73.56%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tenax Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Immunocore	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Tenax Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-63.18%	-58.93%
Immunocore	-6.68%	-7.07%	-2.55%

Summary

Tenax Therapeutics beats Immunocore on 10 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Tenax Therapeutics has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	60.67	-$137.17M	-$1.07	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

1.7% of Tenax Therapeutics shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tenax Therapeutics had 15 more articles in the media than Generate Biomedicines. MarketBeat recorded 17 mentions for Tenax Therapeutics and 2 mentions for Generate Biomedicines. Tenax Therapeutics' average media sentiment score of 0.75 beat Generate Biomedicines' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Tenax Therapeutics	N/A	-63.18%	-58.93%

Generate Biomedicines currently has a consensus price target of $25.40, indicating a potential upside of 77.13%. Tenax Therapeutics has a consensus price target of $37.67, indicating a potential upside of 162.85%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Tenax Therapeutics beats Generate Biomedicines on 10 of the 14 factors compared between the two stocks.

How does Tenax Therapeutics compare to Zymeworks?

Tenax Therapeutics (NASDAQ:TENX) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Tenax Therapeutics has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Zymeworks	$105.96M	15.03	-$81.13M	-$1.37	N/A

Tenax Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Tenax Therapeutics presently has a consensus target price of $37.67, suggesting a potential upside of 162.85%. Zymeworks has a consensus target price of $37.33, suggesting a potential upside of 71.18%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Tenax Therapeutics had 11 more articles in the media than Zymeworks. MarketBeat recorded 17 mentions for Tenax Therapeutics and 6 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.13 beat Tenax Therapeutics' score of 0.75 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-63.18%	-58.93%
Zymeworks	-126.92%	-37.97%	-25.31%

Summary

Zymeworks beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Sarepta Therapeutics currently has a consensus target price of $24.72, indicating a potential upside of 55.68%. Tenax Therapeutics has a consensus target price of $37.67, indicating a potential upside of 162.85%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Sarepta Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

In the previous week, Tenax Therapeutics had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 17 mentions for Tenax Therapeutics and 11 mentions for Sarepta Therapeutics. Tenax Therapeutics' average media sentiment score of 0.75 beat Sarepta Therapeutics' score of 0.69 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.76	-$713.41M	-$0.96	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

Tenax Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Tenax Therapeutics	N/A	-63.18%	-58.93%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Tenax Therapeutics beats Sarepta Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Bausch Health Cos?

Tenax Therapeutics (NASDAQ:TENX) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Bausch Health Cos had 13 more articles in the media than Tenax Therapeutics. MarketBeat recorded 30 mentions for Bausch Health Cos and 17 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.75 beat Bausch Health Cos' score of 0.33 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	6 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Tenax Therapeutics' return on equity of -63.18% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-63.18%	-58.93%
Bausch Health Cos	-10.12%	-561.95%	6.31%

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bausch Health Cos has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A

Tenax Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Tenax Therapeutics currently has a consensus price target of $37.67, suggesting a potential upside of 162.85%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 14.19%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Tenax Therapeutics beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$380.03M	$11.48B	$6.81B	$12.68B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-9.68	793.98	281.02	25.13
Price / Sales	N/A	747.05	575.02	81.09
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	1.38	10.39	11.02	6.21
Net Income	-$52.60M	$2.80B	$3.48B	$347.49M
7 Day Performance	-11.49%	0.31%	0.57%	0.89%
1 Month Performance	-7.31%	-3.69%	-4.14%	-3.60%
1 Year Performance	130.39%	156.59%	63.23%	20.46%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	3.1545 of 5 stars	$14.33 +4.6%	$37.67 +162.9%	+120.3%	$380.03M	N/A	N/A	9	News Coverage Earnings Report Analyst Forecast High Trading Volume
IMCR Immunocore	3.3759 of 5 stars	$33.51 -0.8%	$56.71 +69.2%	+2.5%	$1.72B	$400.02M	N/A	320	Upcoming Earnings Analyst Forecast
GENB Generate Biomedicines	1.6343 of 5 stars	$13.14 -3.9%	$25.40 +93.3%	N/A	$1.68B	$30.30M	N/A	312	High Trading Volume
ZYME Zymeworks	3.4294 of 5 stars	$22.61 -1.7%	$37.33 +65.1%	+74.5%	$1.68B	$105.96M	N/A	460	Positive News Upcoming Earnings
SRPT Sarepta Therapeutics	3.54 of 5 stars	$15.43 -2.9%	$24.72 +60.2%	-6.6%	$1.68B	$2.18B	N/A	1,372	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. IMCR, GENB, ZYME, SRPT, and BHC

How does Tenax Therapeutics compare to Immunocore?

Summary

How does Tenax Therapeutics compare to Generate Biomedicines?

Summary

How does Tenax Therapeutics compare to Zymeworks?

Summary

How does Tenax Therapeutics compare to Sarepta Therapeutics?

Summary

How does Tenax Therapeutics compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. IMCR, GENB, ZYME, SRPT, and BHC

How does Tenax Therapeutics compare to Immunocore?

Does the media prefer TENX or IMCR?

Do institutionals & insiders hold more shares of TENX or IMCR?

Which has better valuation and earnings, TENX or IMCR?

Which has more volatility & risk, TENX or IMCR?

Do analysts recommend TENX or IMCR?

Is TENX or IMCR more profitable?

Summary

How does Tenax Therapeutics compare to Generate Biomedicines?

Which has better earnings and valuation, GENB or TENX?

Do institutionals & insiders have more ownership in GENB or TENX?

Does the media refer more to GENB or TENX?

Is GENB or TENX more profitable?

Do analysts rate GENB or TENX?

Summary

How does Tenax Therapeutics compare to Zymeworks?

Which has stronger valuation and earnings, TENX or ZYME?

Which has more risk and volatility, TENX or ZYME?

Do analysts rate TENX or ZYME?

Do insiders and institutionals believe in TENX or ZYME?

Does the media refer more to TENX or ZYME?

Is TENX or ZYME more profitable?

Summary

How does Tenax Therapeutics compare to Sarepta Therapeutics?

Do analysts prefer SRPT or TENX?

Which has more risk and volatility, SRPT or TENX?

Does the media prefer SRPT or TENX?

Which has preferable earnings & valuation, SRPT or TENX?

Is SRPT or TENX more profitable?

Do institutionals and insiders believe in SRPT or TENX?

Summary

How does Tenax Therapeutics compare to Bausch Health Cos?

Does the media refer more to TENX or BHC?

Is TENX or BHC more profitable?

Do insiders & institutionals have more ownership in TENX or BHC?

Which has preferable valuation & earnings, TENX or BHC?

Which has more risk and volatility, TENX or BHC?

Do analysts recommend TENX or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools